NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
Clinical Trials
22 trialsNCT06819007 2026-03-05
DO-01
Daiichi Sankyo
Phase 3 Recruiting
NCT06890338 2026-02-24
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Phase 2 Recruiting
NCT05238922 2026-02-10
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT06469281 2026-02-03
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Regeneron Pharmaceuticals
Phase 1 Recruiting
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT04925284 2025-04-04
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
Phase 1 Completed
NCT04516447 2024-11-26
A Study of ZN-c3 in Patients With Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Recruiting
NCT02606305 2024-06-14
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Phase 1/2 Completed
NCT03093155 2024-05-14
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
Phase 2 Completed
NCT04015739 2022-08-17
BOLD
ARCAGY/ GINECO GROUP
Phase 2 Unknown
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT01551745 2021-10-19
Salvage Ovarian FANGâ„¢ Vaccine + Bevacizumab
Gradalis, Inc.
Phase 2 Completed
NCT01146795 2021-02-09
Neoadjuvant Therapy for Ovarian Cancer
Columbia University
Phase 2 Completed
NCT02022917 2021-01-27
Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
Chang Gung Memorial Hospital
Phase 2 Completed
NCT00022659 2019-07-24
Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00079430 2019-07-22
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00085358 2019-07-22
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
National Cancer Institute (NCI)
Phase 1 Completed
NCT01202890 2014-01-08
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
New Mexico Cancer Research Alliance
Phase 1 Terminated
NCT00483782 2013-08-12
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00583622 2013-05-21
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00407563 2012-04-05
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
Accelerated Community Oncology Research Network
Phase 2 Completed